Phase 3 SOLARIS Trial: Subcutaneous Olanzapine LAI Demonstrates Efficacy Without PDSS in Schizophrenia
核心洞察
The phase 3 SOLARIS trial found subcutaneous long-acting injectable olanzapine (TV-44749) significantly improved symptom severity across all three dose groups in patients with schizophrenia (搜索).
No confirmed cases of postinjection delirium/sedation syndrome (搜索) (PDSS) were reported among more than 600 patients and approximately 3,600 injections administered.
The existing intramuscular olanzapine LAI carries a well-documented risk of PDSS, making this subcutaneous formulation a potentially safer alternative if approved.
The phase 3 SOLARIS trial (NCT05693935) has demonstrated that a subcutaneous long-acting injectable (LAI) formulation of olanzapine, designated TV-44749 and developed by Teva Pharmaceuticals, produced significant improvements in symptom severity scores across all three dose groups, with no confirmed cases of postinjection delirium/sedation syndrome (搜索) (PDSS) among more than 600 patients and approximately 3,600 injections administered.
The findings represent a potentially important advance in psychiatric pharmacotherapy, as the currently available intramuscular olanzapine LAI formulation carries a well-documented risk of PDSS — a serious adverse event that has limited broader adoption of the therapy despite its established efficacy.
Trial Design and Safety Profile
The SOLARIS trial evaluated TV-44749, a subcutaneous LAI formulation of olanzapine, across three dose groups. The study enrolled more than 600 patients, and investigators administered approximately 3,600 injections over the course of the trial. Across all dose cohorts, the treatment demonstrated statistically significant improvements in symptom severity scores.
Crucially, no confirmed cases of PDSS were observed throughout the study. This stands in contrast to the known safety profile of the intramuscular formulation, where PDSS has been a persistent clinical concern requiring patients to remain under observation for several hours following each injection.
Clinical Implications for Schizophrenia (搜索) Management
If approved by regulatory authorities, TV-44749 could meaningfully expand the utilization of LAI antipsychotic therapy in a patient population where medication adherence remains a persistent clinical barrier. Long-acting injectable formulations are recognized as an important strategy for improving treatment continuity in schizophrenia (搜索), yet safety concerns associated with existing options have constrained their use.
The subcutaneous route of administration may offer additional practical advantages, potentially simplifying the administration process and reducing the burden on both patients and healthcare providers compared to intramuscular injections.
The Pharmacist's Role in Emerging Psychiatric Formulations
As the therapeutic landscape in psychiatry continues to evolve, health system pharmacists are positioned to play an integral role in translating emerging evidence into clinical practice. This includes counseling patients and providers on next-generation psychiatric formulations, guiding appropriate therapy selection, and implementing the necessary workflows to support safe and effective use of new drug delivery technologies.
The SOLARIS trial results underscore a broader theme in contemporary pharmaceutical care: as science advances, the responsibility of pharmacists to stay current with emerging evidence and apply it to patient care grows correspondingly.